Portola Pharmaceuticals Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 408

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.62B

Portola Pharmaceuticals General Information

Description

Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.

Contact Information

Website
www.portola.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 270 East Grand Avenue
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Vertical(s)
Corporate Office
  • 270 East Grand Avenue
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Portola Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Merger/Acquisition 02-Jul-2020 $1.62B Completed Generating Revenue
14. Secondary Transaction - Open Market Completed Generating Revenue
13. Secondary Transaction - Open Market 30-Jun-2018 Completed Generating Revenue
12. PIPE 03-Feb-2017 Completed Generating Revenue
11. PIPE 25-Jan-2016 Completed Generating Revenue
10. Secondary Transaction - Stock Distribution 18-Feb-2014 Completed Generating Revenue
9. 2PO 17-Oct-2013 Completed Generating Revenue
8. IPO 22-May-2013 Completed Generating Revenue
7. Later Stage VC (Series 1) 14-Dec-2011 $9M $338M Completed Generating Revenue
6. Later Stage VC (Series D) 21-Nov-2011 $89M $329M Completed Generating Revenue
To view Portola Pharmaceuticals’s complete valuation and funding history, request access »

Portola Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series 1
Series D
Series C
Series B 36,750,400 $0.001000 8% $1.31 $1.31 1x $1.31 12.38%
Series A 43,147,400 $0.001000 8% $1 $1 1x $1 14.54%
To view Portola Pharmaceuticals’s complete cap table history, request access »

Portola Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The
Drug Discovery
South San Francisco, CA
408 As of 2019

Lexington, MA
 

Bethesda, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Portola Pharmaceuticals Competitors (58)

One of Portola Pharmaceuticals’s 58 competitors is Dicerna Pharmaceuticals, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Northwest Biotherapeutics Corporation Bethesda, MD
Alaunos Therapeutics Formerly VC-backed Fort Lauderdale, FL
Intas Pharmaceuticals Private Equity-Backed Ahmedabad, India
Genzyme Ireland Corporation Kilmeaden, Ireland
You’re viewing 5 of 58 competitors. Get the full list »

Portola Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Portola Pharmaceuticals Former Investors (37)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abingworth Venture Capital Minority
Adage Capital Management Hedge Fund Minority
Advanced Technology Ventures Venture Capital Minority
AllianceBernstein Asset Manager Minority
Alta Partners Venture Capital Minority
You’re viewing 5 of 37 investors. Get the full list »

Portola Pharmaceuticals Investments (2)

Portola Pharmaceuticals’s most recent deal was a Seed Round with PayPool for . The deal was made on 02-Sep-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PayPool 02-Sep-2022 Seed Round Other Financial Services
Arete Therapeutics 10-May-2007 Early Stage VC Drug Discovery
To view Portola Pharmaceuticals’s complete investments history, request access »

Portola Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Portola Pharmaceuticals’s complete esg history, request access »

Portola Pharmaceuticals FAQs

  • When was Portola Pharmaceuticals founded?

    Portola Pharmaceuticals was founded in 2003.

  • Where is Portola Pharmaceuticals headquartered?

    Portola Pharmaceuticals is headquartered in South San Francisco, CA.

  • What is the size of Portola Pharmaceuticals?

    Portola Pharmaceuticals has 408 total employees.

  • What industry is Portola Pharmaceuticals in?

    Portola Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Portola Pharmaceuticals a private or public company?

    Portola Pharmaceuticals is a Private company.

  • What is the current valuation of Portola Pharmaceuticals?

    The current valuation of Portola Pharmaceuticals is .

  • What is Portola Pharmaceuticals’s current revenue?

    The current revenue for Portola Pharmaceuticals is .

  • How much funding has Portola Pharmaceuticals raised over time?

    Portola Pharmaceuticals has raised $616M.

  • Who are Portola Pharmaceuticals’s investors?

    Abingworth, Adage Capital Management, Advanced Technology Ventures, AllianceBernstein, and Alta Partners are 5 of 37 investors who have invested in Portola Pharmaceuticals.

  • Who are Portola Pharmaceuticals’s competitors?

    Dicerna Pharmaceuticals, Northwest Biotherapeutics, Alaunos Therapeutics, Intas Pharmaceuticals, and Genzyme Ireland are some of the 58 competitors of Portola Pharmaceuticals.

  • When was Portola Pharmaceuticals acquired?

    Portola Pharmaceuticals was acquired on 02-Jul-2020.

  • Who acquired Portola Pharmaceuticals?

    Portola Pharmaceuticals was acquired by Alexion.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process